Assessment of Metabolic & Path Response w/ RCT & ImT Before Surgery in Locally Advanced Esoph and Gastro-esoph Jction CA
Status:
Withdrawn
Trial end date:
2017-12-11
Target enrollment:
Participant gender:
Summary
ARTemIS-Eso is a phase I-II, three-level, open-label trial with a dose-expansion cohort at
recommended schedule in both esophageal cancer histological groups (squamous cell carcinoma
and adenocarcinoma) of RCT and ImT administered prior to surgery.